Total Payments
$189,655
2024 Payments
$11,290
Companies
11
Transactions
189
Medicare Patients
930
Medicare Billing
$137,685
Payment Breakdown by Category
Consulting$126,419 (66.7%)
Other$41,230 (21.7%)
Travel$13,819 (7.3%)
Food & Beverage$4,601 (2.4%)
Research$3,586 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $126,419 | 25 | 66.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,985 | 32 | 15.8% |
| Travel and Lodging | $13,819 | 41 | 7.3% |
| Honoraria | $11,245 | 3 | 5.9% |
| Food and Beverage | $4,601 | 60 | 2.4% |
| Unspecified | $3,586 | 28 | 1.9% |
Payments by Type
General
$186,069
161 transactions
Research
$3,586
28 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $112,992 | 80 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $28,082 | 33 | $0 (2022) |
| CSL Behring | $25,907 | 26 | $0 (2021) |
| GlaxoSmithKline, LLC. | $9,319 | 20 | $0 (2023) |
| Boehringer Ingelheim International GmbH | $7,143 | 12 | $0 (2022) |
| Genentech USA, Inc. | $4,646 | 4 | $0 (2017) |
| SANOFI US SERVICES INC. | $1,351 | 9 | $0 (2017) |
| Aurinia Pharma U.S., Inc. | $118.80 | 1 | $0 (2022) |
| Gilead Sciences Inc | $53.00 | 2 | $0 (2017) |
| United Therapeutics Corporation | $26.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,290 | 6 | Boehringer Ingelheim Pharmaceuticals, Inc. ($11,290) |
| 2023 | $21,339 | 27 | Boehringer Ingelheim Pharmaceuticals, Inc. ($12,020) |
| 2022 | $37,457 | 16 | Boehringer Ingelheim Pharmaceuticals, Inc. ($33,993) |
| 2021 | $33,118 | 24 | Boehringer Ingelheim Pharmaceuticals, Inc. ($15,691) |
| 2020 | $23,840 | 14 | Boehringer Ingelheim Pharmaceuticals, Inc. ($14,586) |
| 2019 | $36,076 | 41 | Boehringer Ingelheim Pharmaceuticals, Inc. ($20,336) |
| 2018 | $5,266 | 5 | Boehringer Ingelheim International GmbH ($2,400) |
| 2017 | $21,269 | 56 | Actelion Pharmaceuticals US, Inc. ($6,458) |
All Payment Transactions
189 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $118.02 | General |
| Category: RESPIRATORY | ||||||
| 07/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $19.64 | General |
| 07/01/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $10,780.00 | General |
| Category: RESPIRATORY | ||||||
| 07/01/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: RESPIRATORY | ||||||
| 07/01/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: RESPIRATORY | ||||||
| 05/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $197.03 | General |
| Category: RESPIRATORY | ||||||
| 12/27/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Consulting Fee | Cash or cash equivalent | $7,083.65 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $460.20 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 12/06/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $179.10 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 12/06/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $130.97 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 12/06/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $65.76 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 12/06/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $37.75 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 12/06/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $15.87 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 12/06/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $14.02 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 10/24/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | Cash or cash equivalent | $58.00 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 10/24/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | Cash or cash equivalent | $27.28 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 09/27/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $315.38 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 09/27/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $246.14 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 09/27/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $196.84 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 09/27/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $123.85 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 09/27/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $98.43 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 09/27/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $86.24 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 09/27/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $63.80 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 09/27/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $51.88 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
| 09/27/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | — | In-kind items and services | $46.22 | Research |
| Study: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR • Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | GlaxoSmithKline, LLC. | $2,235 | 19 |
| Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study | SANOFI US SERVICES INC. | $1,351 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 203 | 277 | $82,710 | $29,340 |
| 2022 | 4 | 180 | 260 | $73,145 | $28,601 |
| 2021 | 8 | 274 | 386 | $107,417 | $44,040 |
| 2020 | 9 | 273 | 400 | $102,830 | $35,704 |
Total Patients
930
Total Services
1,323
Medicare Billing
$137,685
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 120 | 190 | $55,270 | $19,255 | 34.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $12,171 | $4,344 | 35.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 22 | 24 | $9,985 | $3,619 | 36.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 22 | $4,635 | $1,741 | 37.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 11 | 11 | $649.00 | $380.93 | 58.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 127 | 202 | $53,598 | $21,041 | 39.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 24 | 29 | $10,237 | $4,442 | 43.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 18 | 18 | $7,260 | $2,439 | 33.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 11 | $2,050 | $678.50 | 33.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 115 | 159 | $41,817 | $17,393 | 41.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 60 | 85 | $30,005 | $13,087 | 43.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 28 | 71 | $12,283 | $4,638 | 37.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 18 | 18 | $9,089 | $3,418 | 37.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $7,290 | $2,731 | 37.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $4,411 | $1,695 | 38.4% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 13 | 13 | $1,612 | $797.16 | 49.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 14 | 14 | $910.00 | $280.36 | 30.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 128 | 195 | $51,285 | $17,507 | 34.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 27 | 79 | $13,667 | $5,098 | 37.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 27 | 32 | $11,296 | $4,042 | 35.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 17 | 17 | $6,817 | $2,349 | 34.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 19 | 20 | $5,260 | $2,008 | 38.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $5,533 | $1,893 | 34.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 14 | 14 | $4,592 | $1,604 | 34.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 18 | 20 | $3,600 | $971.26 | 27.0% |
About Virginia Steen
Virginia Steen is a Allergy & Immunology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073513818.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Virginia Steen has received a total of $189,655 in payments from pharmaceutical and medical device companies, with $11,290 received in 2024. These payments were reported across 189 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($126,419).
As a Medicare-enrolled provider, Steen has provided services to 930 Medicare beneficiaries, totaling 1,323 services with total Medicare billing of $137,685. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Other Specialties Rheumatology
- Location Washington, DC
- Active Since 07/22/2005
- Last Updated 03/15/2012
- Taxonomy Code 207RA0201X
- Entity Type Individual
- NPI Number 1073513818
Products in Payments
- OFEV (Drug) $76,387
- UPTRAVI (Drug) $19,735
- Privigen (Biological) $11,367
- BENLYSTA (Biological) $9,319
- Actemra (Biological) $4,646
- OPSUMIT (Drug) $1,890
- SAR156597 (Drug) $1,351
- Hizentra (Biological) $900.00
- OPSUMIT MACITENTAN (Drug) $241.98
- TYVASO (Drug) $26.00
- ACTHAR (Biological) $17.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Allergy & Immunology Doctors in Washington
Autumn Burnette, Md, MD
Allergy & Immunology — Payments: $2.1M
Allergy & Immunology $2.1M
Stephen Mitchell, Md, MD
Allergy & Immunology — Payments: $1.3M
Allergy & Immunology $1.3M
Daniel Ein, Md, MD
Allergy & Immunology — Payments: $54,179
Allergy & Immunology $54,179
Dr. Henry Fishman
Allergy & Immunology — Payments: $18,707
Allergy & Immunology $18,707
Carla Davis, Md, MD
Allergy & Immunology — Payments: $17,725
Allergy & Immunology $17,725
Eliane Abou-Jaoude
Allergy & Immunology — Payments: $11,327
Allergy & Immunology $11,327